Online citations, reference lists, and bibliographies.
← Back to Search

PEG-PLA Nanoparticles As Carriers For Nasal Vaccine Delivery.

A. Vila, A. Sánchez, C. Évora, I. Soriano, J. L. Vila Jato, M. Alonso
Published 2004 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This report presents an overview of the potential of nanoparticles as nasal carriers for drug/vaccine administration. In addition, this report shows, for the first time, the efficacy of polylactic acid nanoparticles coated with a hydrophilic polyethyleneglycol coating (PEG-PLA nanoparticles) as carriers for the nasal transport of bioactive compounds. For this purpose, tetanus toxoid (TT), a high molecular weight protein (Mw 150,000 Da), was chosen as a model antigen and encapsulated in the PEG-PLA nano- and microparticles (200 nm and 1.5 microm respectively). These nanosystems were first characterized for their stability in the presence of lysozyme and also for their size, electrical charge, loading efficiency, in vitro release of antigenically active toxoid and afterwards, these formulations were administered intranasally to mice and the systemic and mucosal anti-tetanus responses were evaluated for up to 24 weeks. Additionally, PEG-PLA particles labeled with rhodamine 6G were administered intranasally to rats in order to visualize their interaction with the nasal mucosae by fluorescence microscopy. Their behavior was compared with that of the well known PLA nanoparticles (200 nm). The results showed that PLA nanoparticles suffered an immediate aggregation upon incubation with lysozyme, whereas the PEG-coated nanoparticles remained totally stable. The antibody levels elicited following i.n. administration of PEG-coated nanoparticles were significantly higher than those corresponding to PLA nanoparticles. Furthermore, PEG-PLA nanoparticles generated an increasing and a long lasting response. The qualitative fluorescence microscopy studies revealed that PEG-PLA particles are able to cross the rat nasal epithelium. These studies indicate that the PEG coating around the particles has a role in stabilizing PLA particles in mucosal fluids and that it facilitates the transport of the nanoencapsulated antigen, hence eliciting a high and long lasting immune response.
This paper references
10.1128/IAI.63.4.1195-1200.1995
Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres.
R. Shahin (1995)
10.1002/(SICI)1097-4636(199810)42:1<45::AID-JBM7>3.0.CO;2-O
Protein encapsulation within polyethylene glycol-coated nanospheres. I. Physicochemical characterization.
P. Quellec (1998)
10.1080/026520499289338
Comparative degradation study of biodegradable microspheres of poly(DL-lactide-co-glycolide) with poly(ethyleneglycol) derivates.
J. García (1999)
10.1517/17425247.1.1.185
Innovative therapeutics: from molecules to medicines
W. Jiskoot (2004)
10.1016/J.IJPHARM.2004.09.002
PLA-PEG particles as nasal protein carriers: the influence of the particle size.
A. Vila (2005)
10.1016/S1461-5347(00)00281-9
Intranasal vaccines: forthcoming challenges.
Partidos (2000)
10.1016/J.EJPB.2003.09.006
Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.
A. Vila (2004)
10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4
Novel hydrophilic chitosan‐polyethylene oxide nanoparticles as protein carriers
P. Calvo (1997)
10.1016/J.BIOMATERIALS.2005.03.005
Interaction of various pectin formulations with porcine colonic tissues.
L. Liu (2005)
10.1016/S0939-6411(96)00013-6
Aqueous pseudolatex of zein for film coating of solid dosage forms
P. B. O'donnell (1997)
10.1016/S0928-0987(03)00019-8
Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha.
A. Sánchez (2003)
10.1517/17425247.2.2.205
Bioadhesive properties of pegylated nanoparticles
K. Yoncheva (2005)
10.1016/J.COLSURFB.2005.06.004
Methotrexate-loaded biodegradable polymeric micelles: preparation, physicochemical properties and in vitro drug release.
Y. Zhang (2005)
10.1016/0264-410X(95)00184-3
Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.
A. Moore (1995)
10.1016/S0378-5173(99)00239-2
Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume.
J. Eyles (1999)
10.1016/S0264-410X(96)90048-1
European Commission COST/STD Initiative. Report of the expert panel VI. Concerted efforts in the field of mucosal immunology.
J. Holmgren (1996)
10.1023/A:1011922819926
Stealth PLA-PEG Nanoparticles as Protein Carriers for Nasal Administration
M. Tobío (2004)
10.1016/J.JCONREL.2004.07.030
Transmucosal macromolecular drug delivery.
C. Prego (2005)
10.1111/j.2042-7158.1993.tb05532.x
Immune Response to Nasal Delivery of Antigenically Intact Tetanus Toxoid Associated with Poly(l‐lactic acid) Microspheres in Rats, Rabbits and Guinea‐pigs
A. Almeida (1993)
10.1002/PAT.280
PLA‐PEG nanospheres: new carriers for transmucosal delivery of proteins and plasmid DNA
A. Vila (2002)
10.1016/S0939-6411(97)00056-8
Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres
M. D. Blanco (1997)
10.1016/S0169-409X(00)00123-X
Polysaccharide colloidal particles as delivery systems for macromolecules.
K. Janes (2001)
10.1586/14760584.4.2.185
Nanoparticles as carriers for nasal vaccine delivery
M. Köping-Höggård (2005)
10.1016/S0168-3659(99)00197-2
Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits.
J. Eyles (2000)
10.1016/S0168-3659(01)00486-2
Design of biodegradable particles for protein delivery.
A. Vila (2002)
10.1023/A:1018908705446
Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles
R. Fernández-Urrusuno (2004)
10.1016/J.BIOPHA.2004.01.007
Nanomedicines for overcoming biological barriers.
M. Alonso (2004)
10.1016/0168-3659(95)00163-8
Parenteral protein delivery systems using biodegradable polyesters of ABA block structure, containing hydrophobic poly(lactide-co-glycolide) A blocks and hydrophilic poly(ethylene oxide) B blocks
T. Kissel (1996)
10.1016/S0264-410X(99)00313-8
Improved immunogenicity of a core-coated tetanus toxoid delivery system.
M. Tobío (1999)
10.1128/IAI.67.5.2643-2648.1999
Single-Dose Mucosal Immunization with Biodegradable Microparticles Containing a Schistosoma mansoniAntigen
B. Baras (1999)
10.1023/A:1011929016601
Chitosan and its use as a pharmaceutical excipient.
L. Illum (1998)
10.1016/0264-410X(94)00008-B
Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles.
E. Cahill (1995)
10.1016/0167-5699(92)90158-4
The role of nasopharyngeal lymphoid tissue.
C. Kuper (1992)
10.1016/S0264-410X(97)00249-1
Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse.
J. Eyles (1998)
10.1093/INFDIS/167.3.752
Microencapsulated human parainfluenza virus induces a protective immune response.
R. Ray (1993)
10.1023/A:1012128907225
Chitosan and Chitosan/Ethylene Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel Carriers for Proteins and Vaccines
P. Calvo (2004)
10.1023/A:1007582911958
Visual Evidence of Acidic Environment Within Degrading Poly(lactic-co-glycolic acid) (PLGA) Microspheres
K. Fu (2004)
10.1016/S0927-7765(99)00157-5
The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration.
Tobío (2000)
10.1126/SCIENCE.8128245
Biodegradable long-circulating polymeric nanospheres.
R. Gref (1994)
10.1023/A:1011063232257
Tetanus Toxoid Loaded Nanoparticles from Sulfobutylated Poly(Vinyl Alcohol)-Graft-Poly(Lactide-co-Glycolide): Evaluation of Antibody Response After Oral and Nasal Application in Mice
T. Jung (2004)
10.1023/A:1012029517394
The Oral Absorption of Micro- and Nanoparticulates: Neither Exceptional Nor Unusual
A. Florence (2004)
10.1016/0264-410X(96)00063-1
Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres.
C. Yan (1996)
10.1016/0168-3659(95)00053-B
Non-stealth (poly(lactic acid/albumin)) and stealth (poly(lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers
T. Verrecchia (1995)
10.1046/j.1365-3083.1997.d01-159.x
Nasal Lymphoid Tissue (NALT) as a Mucosal Immune Inductive Site
H. Wu (1997)



This paper is referenced by
10.1021/BK-2013-1150.CH001
The adjuvant effect of emerging nanomaterials: A double-edged sword
H. Ren (2013)
Desarrollo de nuevos vehículos para la administración de vacunas genéticas
N. Csaba (2005)
Immunological Evaluation of Biodegradable Particle Based Nanoparticles Encapsulating OMP Antigen as Potential Vaccine Candidate
P. R. Rauta (2016)
10.1517/17425247.2.2.205
Bioadhesive properties of pegylated nanoparticles
K. Yoncheva (2005)
10.1007/s41745-018-0063-7
Biomaterials for Engineering Immune Responses
S. Jhunjhunwala (2018)
10.1371/journal.pone.0060728
Evaluation of Physical and Mechanical Properties of Porous Poly (Ethylene Glycol)-co-(L-Lactic Acid) Hydrogels during Degradation
Yu-Chieh Chiu (2013)
10.1016/B978-0-323-39981-4.00010-5
Polymer-Based Nanoparticles as Modern Vaccine Delivery Systems
Laure Lambricht (2017)
10.1016/J.VACCINE.2006.06.021
Nano- and microparticles as adjuvants in vaccine design: success and failure is related to host natural antibodies.
M. Sinyakov (2006)
10.1016/B978-0-08-102985-5.00025-5
Nanoparticles for mucosal vaccine delivery
Aneesh Thakur (2020)
10.1201/9781420008449.CH20
Nanoparticles as Adjuvant-Vectors for Vaccination
S. Espuelas (2007)
10.5731/pdajpst.2011.00704
Pulmonary Drug Delivery: Novel Pharmaceutical Technologies Breathe New Life into the Lungs
B. Nanjwade (2011)
Iranian Journal of Pathology Nanomedicine
M. Bahadori (2006)
10.1007/82_2011_140
Recent advances in microparticle and nanoparticle delivery vehicles for mucosal vaccination.
E. McNeela (2012)
10.3390/molecules21070867
Advanced Nanobiomaterials: Vaccines, Diagnosis and Treatment of Infectious Diseases
Eva Torres-Sangiao (2016)
10.1016/J.BIOMATERIALS.2005.03.005
Interaction of various pectin formulations with porcine colonic tissues.
L. Liu (2005)
10.1016/B978-0-323-39981-4.00015-4
Nasal Vaccine Delivery
Madeshwaran Ramvikas (2017)
10.1016/j.micpath.2018.10.023
A novel antigen of Mycobacterium tuberculosis and MPLA adjuvant co-entrapped into PLGA:DDA hybrid nanoparticles stimulates mucosal and systemic immunity.
F. Khademi (2018)
Strategy of oral vaccination by polymeric nanoparticles : M cell targeting or bioadhesion
Laurence Plapied (2011)
10.1039/C6PY01113F
Poly(D,L-lactic acid)-block-poly(N-(2-hydroxypropyl)methacrylamide) nanoparticles for overcoming accelerated blood clearance and achieving efficient anti-tumor therapy
N. Du (2016)
10.1517/17425247.1.1.185
Innovative therapeutics: from molecules to medicines
W. Jiskoot (2004)
10.1586/erv.10.89
Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses
M. Oyewumi (2010)
10.3109/03639040903261989
Microencapsulation of cytarabine using poly(ethylene glycol)–poly(ε-caprolactone) diblock copolymers as surfactant agents
R. Diab (2010)
10.1124/pr.111.005363
Physical and Chemical Strategies for Therapeutic Delivery by Using Polymeric Nanoparticles
José M. Morachis (2012)
10.1016/J.COLSURFB.2005.06.004
Methotrexate-loaded biodegradable polymeric micelles: preparation, physicochemical properties and in vitro drug release.
Y. Zhang (2005)
10.1586/14760584.4.2.185
Nanoparticles as carriers for nasal vaccine delivery
M. Köping-Höggård (2005)
10.1016/j.ejpb.2010.12.017
Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design.
Xinran Li (2011)
10.1016/j.jconrel.2014.04.017
Assessment of PEG on polymeric particles surface, a key step in drug carrier translation.
Jean-Michel Rabanel (2014)
Nanosphères polymères à couverture de hyaluronate pour la délivrance ciblée de molécules actives dans le traitement des affections du cartilage
Hamed Laroui (2007)
PLGA-PEG-PLGA microspheres as a delivery vehicle for antisense oligonucleotides to CTGF: Implications on post-surgical peritoneal adhesion prevention
J. Azeke (2007)
10.1016/j.actbio.2016.11.012
Poly(lactic acid)-based particulate systems are promising tools for immune modulation.
Carina Peres (2017)
10.17077/etd.h0z4bv8z
Uptake and distribution of ultrafine nanoparticles and microemulsions from the nasal mucosa
B. C. Bejgum (2017)
10.1002/9780470431818.CH10
Nanotechnology to Improve Oral Drug Delivery
M. Bhavsar (2008)
See more
Semantic Scholar Logo Some data provided by SemanticScholar